3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
78
Neoplasm Metastasis
16
Neoplasms
9
Breast Neoplasms, Male
9
Brain Neoplasms
6
Urinary Bladder Neoplasms
5
Ovarian Neoplasms
5
Head and Neck Neoplasms
4
Colorectal Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Carcinoma, Squamous Cell
3
Carcinoma, Ovarian Epithelial
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Pancreatic Neoplasms
2
Neuroma, Acoustic
2
Neurofibromatosis 2
2
Inflammatory Breast Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Ductal, Breast
2
Salivary Gland Neoplasms
1
Recurrence
1
Prolactinoma
1
Pituitary Neoplasms
1
Patient Compliance
1
Neuroectodermal Tumors, Primitive
1
Interventions
Cyclophosphamide
115
Dexamethasone
70
fludarabine phosphate
57
Cytarabine
56
fludarabine
52
Rituximab
51
Peripheral Blood Stem Cell Transplantation
40
Etoposide
40
Gemcitabine
39
Lenalidomide
38
pembrolizumab
33
Radiotherapy
33
Busulfan
33
Filgrastim
32
Carboplatin
31
Methotrexate
30
Cyclosporine
29
Cisplatin
29
Bortezomib
29
Mycophenolic Acid
28
Melphalan
28
venetoclax
27
Paclitaxel
26
Whole-Body Irradiation
24
Antilymphocyte Serum
23
Temozolomide
22
Granulocyte Colony-Stimulating Factor
20
Calcium Dobesilate
20
Bevacizumab
20
Tacrolimus
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Recurrence
×
Lapatinib
×
Clear all
NCT00888810
2009-04-28
TOPO-LAPA
Centre Francois Baclesse
Phase 2
Terminated
39 enrolled